Grifols International S.A

Article

Sponsored Content

Grifols Partnership is a business-to-business contract development and manufacturing platform for sterile solutions and lipid emulsions with over 75 years’ experience in producing intravenous solutions for the pharmaceutical industry worldwide.

Grifols is one of the world’s leading pharmaceutical companies with 30 subsidiaries, and operations in more than 100 countries. Grifols Partnership is a CDMO for parenteral solutions and lipid emulsions with over 75 years’ experience in producing intravenous solutions for the pharmaceutical industry worldwide. A solid commitment to quality makes Grifols Partnership a reliable and efficient strategic partner for your contract manufacturing needs.

 

Our high level of specialization allows us to offer pharmaceutical development and manufacturing for products that require advanced technology and complex production processes.
Grifols Partnership has two FDA and GMP approved manufacturing facilities in Spain for intravenous solutions that have parametric release certification.

 

Grifols Partnership works together with the customer from the early stages of development to commercial manufacturing industrial batches.

   •    Pre-formulation and development
   •   Scale-up and technology transfer of methods
   •   Validation batches
   •   Process scale-up and pilot production including 10/300L reactors
   •   ICH stability studies
   •   Analytical development and validation
   •   Clinical batches
   •   Dossier support documentation
   •   Commercial manufacturing of industrial batches
   •   Labelling and packaging

 

Technological capabilities:
   •    Aqueous (LVP & SVP)
   •   Diluents for reconstitution
   •   Emulsion technology
   •   Form Fill Seal (FFS) technology for PP bags
   •   Manufacture and filling of oxygen and light sensitive products
   •   Terminal sterilization

 

Container Technologies
   •   Vials: 5ml to 50ml, glass
   •   Glass Bottles: 50ml to 500ml
   •   Flexible Polypropylene IV Bags: 50ml to 3000ml

 

Contact Details:

Company name: Grifols International S.A
Website: www.partnership.grifols.com
E-mail: marga.vines@grifols.com
Stand/Booth number: 41J52

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Related Content